‘The initiation of the non-inferiority research represents a significant milestone for Cardica as we continue on the path toward prepared commercialization of MicroCutter products in the United States,’ stated Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica, Inc. ‘We expect enrollment to take approximately half a year, and we intend to include the outcomes of the study in a 510 submission to the U.S.Recently, Nicholas Gonzalez, M.D. Authored The Trophoblast and the Origins of Malignancy – which evaluations Dr. Beard’s function from the perspective of modern molecular biology. Don’t miss this rare possibility to learn more on the subject of a wonderfully successful method of treating cancer. This Thursday night at 6pm Pacific / 9pm Eastern The NaturalNews Chat Hour begins, and registration is Free of charge. Follow this link – and enter your email free of charge show details + a free of charge gift! THE REALITY about the NCI-NCCAM Clinical Research In 1998, the NCI approved financing for a big scale clinical study, where Dr. Gonzalez’s nutritional-enzyme therapy will be when compared to best obtainable chemotherapy in the treating patients identified as having inoperable pancreatic cancer.